TME Pharma and TMS Co believe that this environment is favorable for the planned financing through TMS’ Subsidiary and intend to leverage the strong and positive momentum for further clinical ...
When looking at the earnings of AI-related companies, which numbers do you focus on?There are many figures to check, such as ...
Cash from operations totaled $21.0 billion despite Middle East outages; Shell expects a non-cash Q4 loss estimated at $6.4 ...
The Strategic Review is intended to provide shareholders with a fair, balanced and comprehensive review of the development and performance of the Company during the year ended 30th June 2026, its ...
Current CEO, Tony Zook, to then transition to Executive Chairman Expanded Medicare-coverage for RaDaR ST to include ...
The programme has a roughly three-month term; Shell intends to finish before Q4 2026 results, subject to markets, with a 470 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results